Regulation

Survival projections aren’t enough to sway ODAC to recommend Keytruda for new TNBC indications

FDA and its Oncology Drugs Advisory Committee want more survival data before supporting an accelerated approval of Keytruda as an adjuvant and neoadjuvant therapy for triple-negative breast cancer — a decision that